Compare FLGT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | CMPX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.4M | 926.7M |
| IPO Year | 2016 | 2020 |
| Metric | FLGT | CMPX |
|---|---|---|
| Price | $14.26 | $5.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $28.33 | $14.43 |
| AVG Volume (30 Days) | 310.5K | ★ 1.7M |
| Earning Date | 06-01-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,730,000.00 | $850,000.00 |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $9.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.57 | $1.33 |
| 52 Week High | $31.04 | $6.88 |
| Indicator | FLGT | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 15.95 | 40.19 |
| Support Level | N/A | $4.78 |
| Resistance Level | $19.96 | $5.86 |
| Average True Range (ATR) | 0.99 | 0.31 |
| MACD | -0.73 | -0.12 |
| Stochastic Oscillator | 2.02 | 23.34 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.